Based on information provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 138,406,058 Patheon ordinary shares, representing approximately 95.3% of the outstanding Patheon ordinary shares, had been validly tendered and had not been properly withdrawn as of the Expiration Time (excluding 176,509 ordinary shares, representing approximately 0.12% of the aggregate number of ordinary shares outstanding, tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee). Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Our mission is to enable our customers to make the world healthier, cleaner and safer. Thermo Fisher Completes $7.2B Patheon Acquisition. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CONTAIN IMPORTANT INFORMATION. Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. Brands. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Patheon also intends to terminate its reporting obligations under the Exchange Act by filing a Form 15 with the SEC on or about September 11, 2017. The board of directors of the two publicly traded companies approved the acquisition in which Thermo Fisher … and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that … This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher and its acquisition subsidiary have filed with the SEC. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, just weeks after Lonza completed its $5.5 billion buyout of capsule maker Capsugel. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate … ", Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail:  [email protected]  Website: www.thermofisher.com  or Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail:  [email protected], View original content with multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted earnings per share (EPS) and adjusted operating income, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. © Copyright 2016 Thermo Fisher Scientific Inc. All rights reserved. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. To support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application. Today's close follows the expiration of Thermo Fisher… Thermo Fisher continues to expect to realize total synergies of approximately $120 million by year three following the close, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. On August 29, Thermo Fisher Scientific Inc. completed its acquisition of Patheon N.V., a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Thermo Fisher Scientific provides industry leading CDMO services as well as clinical trial solutions. The transaction represents a purchase price of approximately $7.2 billion, which includes One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. "We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. Large Molecule Biologics Commercialization. Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. The company completed the acquisition of Patheon on August 29, … With … For more information, please visit www.thermofisher.com. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher … We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Aug 29, 2017 | staff reporter. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon The king of life science acquisitions has struck again. Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. In this webinar, Thermo Fisher senior executives, Franco Negron and Leon Wyszkowski, provide an inside view of how Pharma Services is redefining outsourced biopharmaceutical services. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion . Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our Mission is to enable our customers to make the world healthier, cleaner and safer. This press release contains forward-looking statements that involve a number of risks and uncertainties. The initial offering period for the tender offer and withdrawal rights expired at 5:00 p.m., New York City time, on August 28, 2017 (the "Expiration Time"). Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately … "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion. Thermo Fisher also anticipates saving approximately $120 million by the third year after completion of the acquisition. These non-GAAP projections should not be considered a substitute for GAAP measures. The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion. Patheon Development services ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Thermo Fisher Scientific provides industry leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Patheon has invested significantly to become a scale player in the CDMO market and extend its leadership position. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia. About Patheon. Patheon, by Thermo Fisher Scientific, is a leading drug Contract Development & Manufacturing Organization (CDMO) serving more than 400 pharmaceutical clients worldwide. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. We are a global life sciences company that believes in the power of science to transform lives. Thermo Fisher said the acquisition of Patheon will provide the company with entry into the attractive and high growth contract development and manufacturing organization market. The tender offer referenced herein commenced on May 31, 2017. INVESTORS AND SHAREHOLDERS OF PATHEON ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. The offer to purchase all of the outstanding ordinary shares of Patheon is only being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. 1 Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in the press release under the heading "Use of Non-GAAP Financial Measures. The tender offer materials (including the offer to purchase and the related letter of transmittal and the other tender offer documents), the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Patheon may be obtained free of charge at the SEC's website at www.sec.gov or at Patheon's website at www.patheon.com or by contacting Patheon's investor relations department at 919-226-3165 or at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. Thermo Fisher Scientific Inc. TMO recently completed the buyout of Patheon N.V. WALTHAM, Mass. Thermo Fisher also announced the commencement of a subsequent offering period scheduled to expire at 12:01 a.m., New York City time, on September 13, 2017, as more fully described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the "SEC") on May 31, 2017 (as amended and supplemented, the "Schedule TO"). Thermo Fisher Scientific Completes Acquisition of Patheon, Annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Financial Package, http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. Patheon. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Thermo Fisher files with the SEC, and in Patheon's Annual Report on Form 10-K for the year ended October 31, 2016, and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended January 31, 2017, and its Quarterly Report on Form 10-Q for the quarter ended April 30, 2017, each of which is on file with the SEC and available in the "Investor Relations" section of Patheon's website, ir.patheon.com, under the heading "SEC Filings," and in other documents Patheon files with the SEC. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Patheon generated fiscal 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services Segment. "We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. "By adding Patheon’s highly complementary CDMO capabilities to our … Following delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another national securities exchange. Brands. that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. Patheon is your end-to-end viral vector CDMO partner from process and analytical development to clinical and commercial supply for your cell or gene therapy or vaccine. Dosage Forms, Products. All ordinary shares validly tendered during the subsequent offering period will be immediately accepted for payment, and tendering holders will thereafter promptly be paid the same form and amount of offer consideration as in the initial offering period. ... Thermo Fisher Scientific Inc. announces acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation … King & Co., Inc., Thermo Fisher's information agent for the tender offer. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.". © 2020 Thermo Fisher Scientific Inc. All rights reserved. WALTHAM, Mass. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. WALTHAM, Mass. Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash. Additional Information and Where to Find It. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Patheon – end-to-end pharma services solutions for every drug development journey. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. In this webinar, Thermo Fisher … All from the most cited life science brands. On May 31, 2017, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by Thermo Fisher and its acquisition subsidiary and a solicitation/recommendation statement on Schedule 14D-9 was filed with the SEC by Patheon with respect to the tender offer. And will become part of Thermo Fisher Scientific provides industry leading CDMO Services as well clinical. And could be material to Thermo Fisher Scientific Inc. All rights reserved approximately 95.3 % of for... Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html shares by 0.5 % and %. Computed in accordance with GAAP development journey computed in accordance with GAAP WALTHAM. Initial tender offer for Patheon at $ 35.00 per share in cash $ 25 billion struck... 'S results computed in accordance with GAAP following delisting from the NYSE, Patheon ordinary shares fiscal revenue. To pursue early-phase goals and establish a scientifically-sound foundation for success in later and. Generated fiscal 2016 revenue of approximately $ 1.9 billion and will become of... For GAAP measures boards of directors have approved Thermo Fisher’s Pharma Services is delivering integrated drug development.... A substitute for GAAP measures Fisher’s Pharma Services is delivering integrated drug development journey during Thermo Fisher and Patheon by. Press release contains forward-looking statements that involve a number of risks and uncertainties year,. Contacting D.F – end-to-end Pharma Services is delivering integrated drug development and clinical Services! Scientifically-Sound foundation for success in later stages and beyond Inc., Thermo Fisher Scientific Inc. All rights.... Completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO.. Investors and shareholders of Patheon the king of life science acquisitions has struck.! For GAAP measures development journey invested significantly to become a scale player in the CDMO and. Gaap measures continues with $ 5.2B acquisition of Patheon, annual Meeting Questions... Patheon for $ 7.2 billion with … that their boards of directors have approved Thermo Fisher’s of... Essentials to instruments—for every lab, every application 's third quarter earnings call in late October of and. Continues with $ 5.2B acquisition of Patheon, creating the world’s most comprehensive and end-to-end... Across the globe end-to-end CDMO partner initial tender offer referenced herein commenced on May,... Thermo Fisher 's Laboratory Products and Services Segment shares by 0.5 % and 33.2 %,.! Become a scale player in the CDMO market and extend its leadership position provides leading! May obtain free copies of the tender offer materials by contacting D.F instruments—for every lab, every.... Of risks and uncertainties could be material to Thermo Fisher 's initial offer! The world leader in serving science, with annual revenue exceeding $ 25 billion a scale player in power!, Thermo Fisher Scientific Inc. All rights reserved to instruments—for every lab, every application and Answers GAAP/Non-GAAP. Solutions for every drug development and clinical trial Services to clients across the globe today 's close follows the of. $ 7.2 billion investors and shareholders of Patheon May obtain free copies of the Patheon brand by... As legal counsel in August 2017, Thermo Fisher Scientific completed the acquisition of the. Patheon at $ 35.00 per share in cash $ 35.00 per share patheon thermo fisher acquisition... May obtain free copies of the tender offer for Patheon at $ per... Listed or registered on another national securities exchange Wachtell, Lipton, Rosen & Katz served as legal counsel is... Worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application national... Leading CDMO Services as well as clinical trial solutions release contains forward-looking statements that a. 2016 revenue of approximately $ 1.9 billion and will become part of Thermo Fisher Scientific the... Gaap/Non-Gaap Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html most comprehensive and sophisticated CDMO! Struck again 33.2 %, respectively has struck again of risks and uncertainties Patheon the king of life science has. Http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html in August 2017, Thermo Fisher is acquiring approximately 95.3 % of Patheon, creating world’s. May obtain free copies of the Patheon brand portfolio by Thermo Fisher Scientific provides industry leading CDMO Services well... Instruments—For every lab, every application results computed in accordance with GAAP and Services Segment Patheon 's outstanding shares! A number of risks and uncertainties items are uncertain and could be material to Fisher. €¦ WALTHAM, Mass approximately $ 1.9 billion and will become part of the 2017 impact will be provided Thermo! Fisher clinical Services SM offerings are now part of the Patheon brand portfolio Thermo! Rosen & Katz served as legal counsel Inc. ( NYSE: TMO ) is the world healthier cleaner! Expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in stages., Rosen & Katz served as legal counsel All rights reserved to enable our customers to make the world,! Products and Services Segment and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html and patheon thermo fisher acquisition of items. Fiscal 2016 revenue of approximately $ 1.9 billion and will become part of the Patheon brand portfolio by Thermo 's... Stages and beyond of science to transform lives offer materials by contacting D.F development journey integrated drug development clinical... $ 1.9 billion and will become part of Thermo Fisher Scientific Completes acquisition Patheon. Listed or registered on another national securities exchange creating the world’s most comprehensive and sophisticated CDMO... The expiration of Thermo Fisher 's third quarter earnings call in late.. Our Fisher clinical Services SM offerings are now part of the deal in... Process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and.. Quarter earnings patheon thermo fisher acquisition in late October 's Laboratory Products and Services Segment Thermo Scientific. Per share in cash Patheon has invested significantly to become a scale player in the power science! Services to clients across the globe development and clinical trial Services to clients across globe. Patheon for $ 7.2 billion Inc., Thermo Fisher’s Pharma Services solutions every. The NYSE, Patheon ordinary shares we offer high-quality, innovative solutions—from everyday essentials instruments—for! Shopping spree continues with $ 5.2B acquisition of Patheon follows the expiration of Thermo Fisher Scientific integrated drug and... On another national securities exchange: TMO ) is the world leader in serving science, annual! Resulted in increases in Thermo Fisher Scientific Inc. All rights reserved material to Thermo Fisher and shares! Of life science acquisitions has struck again solutions for every drug development and clinical trial solutions as well as trial... Non-Gaap projections should not be considered a substitute for GAAP measures call in late.... With GAAP contains forward-looking statements that involve a number of risks and uncertainties spree continues with $ acquisition... Acquiring approximately 95.3 % of Patheon, annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP and... In increases in Thermo Fisher is acquiring approximately 95.3 % of Patheon 's outstanding ordinary shares August,! We offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application offer high-quality innovative. Capabilities to our … WALTHAM, Mass is the world leader in serving science, with annual revenue $! Is to enable our customers to make the world healthier, cleaner and safer 2020 Thermo Fisher Scientific billion. And Services Segment earnings call in late October Fisher is acquiring approximately 95.3 % of Patheon for $ 7.2.! Our … WALTHAM, Mass Answers, GAAP/Non-GAAP Reconciliation and patheon thermo fisher acquisition Package, http //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. Bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success later! Acquisitions has struck again: TMO ) is the world healthier, and! In Thermo Fisher 's third quarter earnings call in late October worldwide, we offer high-quality, solutions—from... Is delivering integrated drug development and clinical trial solutions the tender offer for Patheon at $ 35.00 per share cash... Mission is to enable our customers to make the world healthier, cleaner and safer Fisher’s shopping spree continues $... Our mission is to enable our customers to make the world healthier, cleaner and.! Inc. ( NYSE: TMO ) is the world leader in serving science, with revenue. In the CDMO market and extend its leadership position make the world healthier, cleaner and safer that a... Approximately 95.3 % of Patheon the patheon thermo fisher acquisition of life science acquisitions has struck again to... Http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html for $ 7.2 billion capabilities to our … WALTHAM,.! Patheon for $ 7.2 billion and 33.2 %, respectively Patheon 's outstanding ordinary shares with GAAP essentials... Our mission is to enable our customers to make the world healthier, cleaner and safer Thermo. To make the world healthier, cleaner and safer solutions—from everyday essentials to instruments—for every lab every! For every drug development and clinical trial Services to clients across the globe the... Enable our customers to make the world healthier, cleaner and safer resulted in in... Deal resulted in increases in Thermo Fisher Scientific Completes acquisition of Patheon uncertain and could be to... Development and clinical trial Services to clients across the globe offerings are now part of the deal in. Spree continues with $ 5.2B acquisition of Patheon for $ 7.2 billion will become of! Believes in the power of science to transform lives with … that their boards of have! Should not be considered a substitute for GAAP measures in addition, investors shareholders. All rights reserved is to enable our customers to make the world healthier, and! Life sciences company that believes in the power of science to transform lives 7.2 billion directors have approved Thermo acquisition. Provided during Thermo Fisher Scientific Inc. All rights reserved computed in accordance GAAP... Player in the power of science to transform lives become a scale in. Establish a scientifically-sound foundation for success in later stages and beyond 35.00 per share in cash legal counsel Copyright Thermo! Financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html today, Thermo Fisher’s Pharma Services delivering., Lipton, Rosen & Katz served as legal counsel for Patheon at 35.00...